New hope for kids with rare blood disorder: drug may cut flares and steroid use

NCT ID NCT04965636

Completed Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This study tested the drug mepolizumab in 16 children aged 6 to 17 with hypereosinophilic syndrome (HES), a rare condition causing too many eosinophils (a type of white blood cell). The goal was to see if mepolizumab could reduce disease flares and lower the need for steroids over 52 weeks. All participants received the drug alongside their usual care, and researchers tracked how many flares occurred and changes in steroid dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mepolizumab
What this could lead to: If it works, this could provide a new treatment option to control hypereosinophilic syndrome in children and reduce their need for steroids.
What could go wrong: This is a small, single-arm study with only 16 participants, so results may not apply to all children. It also does not compare mepolizumab against a placebo or other treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPEREOSINOPHILIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypereosinophilic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPEREOSINOPHILIC SYNDROME

Contacts and locations

Locations

GSK Investigational Site

Rochester, Minnesota, 55905, United States
GSK Investigational Site

Cincinnati, Ohio, 45229, United States
GSK Investigational Site

Cleveland, Ohio, 44106, United States
GSK Investigational Site

Charleston, South Carolina, 29425, United States
GSK Investigational Site

Buenos Aires, 1888, Argentina
GSK Investigational Site

Buenos Aires, C1028AAP, Argentina
GSK Investigational Site

Quilmes, 1878, Argentina
GSK Investigational Site

São Paulo, 05410-002, Brazil
GSK Investigational Site

Sorocaba, 18040-425, Brazil
GSK Investigational Site

Petah Tikva, 49202, Israel
GSK Investigational Site

Rotterdam, 3015 CE, Netherlands
GSK Investigational Site

Ankara, 6230, Turkey (Türkiye)
GSK Investigational Site

Izmir, 35100, Turkey (Türkiye)
GSK Investigational Site

Kayseri, 38039, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.